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Rapid high throughput in vitro screening (HTS) assays are now available for characterizing dose–
responses in assays that have been selected for their sensitivity in detecting estrogen-related endpoints.
For example, EPA’s ToxCast™ program recently released endocrine assay results for more than 1800
substances and the interagency Tox21 consortium is in the process of releasing data for approximately
10,000 chemicals. But such activity measurements alone fall short for the purposes of priority setting
or screening because the relevant exposure context is not considered. Here, we extend the method of
exposure:activity proﬁling by calculating the exposure:activity ratios (EARs) using human exposure esti-
mates and AC50 values for a range of chemicals tested in a suite of seven estrogenic assays in ToxCast™
and Tox21. To provide additional context, relative estrogenic exposure:activity quotients (REEAQ) were
derived by comparing chemical-speciﬁc EARs to the EAR of the ubiquitous dietary phytoestrogen,
genistein (GEN). Although the activity of a substance in HTS-endocrine assays is not a measure of health
hazard or risk, understanding how such a dose compares to human exposures provides a valuable
additional metric that can be used in decision-making; substances with small EARs and REEAQs would
indicate low priority for further endocrine screening or testing.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The intent to reduce, reﬁne, and in some instances, replace the
use of animals in toxicity testing has spurred the development of
high-throughput screening (HTS) assays that eventually may be
used for chemical risk assessment (Judson et al., 2011, 2014;
Thomas et al., 2013). However, to date, many of these in vitro
approaches have demonstrated limited applicability for predicting
in vivo hazard using statistical classiﬁcation methods (Thomaset al., 2012). Initially, it was proposed that the use of classiﬁca-
tion-based prediction models derived from HTS assays results were
capable of matching the in vivo estrogen and androgen results of
the Endocrine Disruptor Screening Program Tier 1 battery with
high balanced accuracies approaching 100%, with notable data
gaps for thyroid and steroidogenesis pathways (Rotroff et al.,
2013a, 2014; Cox et al., 2014). However, when predictive models
were developed from the Rotroff et al. (2013a) dataset using a
cross-validation approach, the balanced accuracies for predicting
in vivo endpoints fell to 85% for estrogen and 79% for androgen
pathways (Cox et al., 2014). Recently, an approach that combines
results from different estrogen pathway-based HTS assays into an
ER Interaction Score has been suggested as a potential tool for pri-
oritizing chemicals for further endocrine screening (Rotroff et al.,
2014). Using a limited set of known positives and known negatives,
the ER Interactions Score methodology was shown to have 91%
sensitivity and 65% speciﬁcity (Ibid.). It is evident from these early
efforts to prioritize chemicals for further estrogen pathway-related
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a transparent, science-based approach for identifying priority che-
micals. There are even larger barriers, including a lack of appropri-
ate HTS assays, for the use of HTS data to predict and prioritize
substances for potential activity in thyroid and steroidogenesis
pathways, (Rotroff et al., 2013a, Paul et al., 2014). Despite these
limitations, such HTS methods hold great promise for improving
the biological basis for priority setting and chemical screening,
and may critically support targeted testing with a tiered, risk-
based framework (Thomas et al., 2013; Pastoor et al., 2014).
While application of HTS results to predict adverse effects for
use in risk assessment may be futuristic, scientiﬁc support is grow-
ing for more immediate applications in priority setting, particular-
ly for endocrine screening, such as within EPA’s tiered testing and
assessment approach, the Endocrine Disruptor Screening Program
(EDSP). EPA has articulated its projected use of HTS methods in
its ‘‘EDSP21’’ vision, which projects utilization of HTS approaches
initially for priority setting, and then as experience is gained, and
commensurate with achieving the requisite degree of scientiﬁc
conﬁdence, as replacements for speciﬁc EDSP screens and tests
(USEPA, 2011, 2014b). Early efforts have been made to characterize
the prediction landscape provided by HTS assay data from the
ToxCast™ and Tox21 programs; these efforts were aimed at pro-
viding methods for ranking chemicals by various metrics. Reif
et al. (2010) presented results of ToxCast™ endocrine screening
using the ToxPi visualization and ranking tool. This endocrine
ToxPi assembled the results of related assays into speciﬁc sections
of a pie chart, and then for each compound, the area reﬂected its
activity in a speciﬁc set of related ToxCast™ assays, with larger
areas suggesting increasing hazard and/or potency. However, ToxPi
does not employ standard reference compounds for normalizing
responses, and instead normalizes each analysis in relation to the
compound with the highest level of activity among the set of sub-
stances evaluated (Patlewicz et al., 2013). This relativistic approach
falls short by not providing potencies benchmarked to reference
substances, and therefore the predicted responses cannot be pri-
oritized within the context of a well-characterized biological effect.
In the absence of this context for priority setting using endocrine-
related HTS data, the point at which a potential biological effect
falls below a regulatory level of concern becomes unclear, and
the relative priorities may even be inconsistent with the large
database of available toxicology data from animal studies. The
strengths of the recent ER Interaction Score method of Rotroff
et al. (2014) include incorporation of data from 13 assays indica-
tive of ER signaling, but a primary weakness is that it uses an
approach which compresses the relative potency information for
screened chemicals, thereby limiting the utility of this method
for priority setting based on integrated consideration of relative
potency, dosimetry, and exposure information. The USEPA present-
ed the integrated bioactivity and exposure ranking (IBER) in
December 2014 (USEPA, 2014b), a ratio based on a model score
similar to the ER Interaction Score and predicted human exposure,
for priority-setting; implementation of this approach will likely
require determination of IBER values that fall below a level of con-
cern for further testing. The need to consider exposure information
along with measures of biologic effects in the initial stages of a risk
assessment was articulated in the RISK21 roadmap (Pastoor et al.,
2014). Using an approach such as the RISK21 roadmap that is prob-
lem formulation based, exposure driven, and expresses the inter-
section of exposure and effect is an effective means for
prioritizing chemicals for further assessment (Pastoor et al., 2014).
Thus, we propose a proﬁling approach that incorporates stan-
dardization to a reference chemical such that the level of concern
is rooted in transparent methodology and becomes obvious and
evident. This proposed exposure:activity proﬁling approach
reﬂects standardization tools used historically in toxicology, suchas dioxin toxicity equivalence factors and environmental estrogen
equivalents (Giesy et al., 2002; Van den Berg et al., 1998, 2006), but
goes beyond toxicity equivalence by incorporating exposure infor-
mation rather than relying solely on a relative measure of potency
or toxicity. Accordingly, the priority status or score of a chemical
would reﬂect both exposure and potency (Borgert et al., 2012,
2013). This score would be presented relative to that of a chosen
reference chemical to provide appropriate context. In summary,
the exposure:activity proﬁling approach we demonstrate herein
supports the use of HTS data in prioritization tasks.2. Exposure:activity proﬁling
Here, as a proof of concept, we illustrate how to apply the
method of exposure:activity proﬁling (Becker et al., 2014) to HTS
endocrine results by calculating exposure:activity ratios (EARs).
This method is a variation of that presented previously
(Wetmore et al., 2012, 2013). To demonstrate this method, we
selected a set of results from seven HTS assays for estrogen recep-
tor interaction in the ToxCast™ and Tox21 assay battery. Because
this is a proof of concept exercise, substances were chosen based
on the availability of (1) estimates of current human oral exposures
and (2) calculated human oral equivalent doses corresponding to
in vitro HTS AC50 values (these values were obtained from Supple-
mental Table 8 of Wetmore et al., 2012). Thus, EARs were devel-
oped using human exposure estimates expressed as oral doses in
mg/kg/d in comparison to predicted oral equivalent doses, also in
mg/kg/d, corresponding to in vitro activity in ToxCast™ assays
(e.g., AC50 or LEC50 values) (Wetmore et al., 2012). If a chemical
was negative in an assay the EAR was defaulted to zero. This
approach enabled us to readily calculate EARs without having to
independently derive oral equivalent values. The operation and
source of the assays is described in detail elsewhere (Judson
et al., 2010; Rotroff et al., 2013a,b, 2014), as are descriptions of
the publicly available chemical library and quality control mea-
sures (Sipes et al., 2013; http://www.epa.gov/ncct/dsstox/). The
derivation of assay AC50 values is reported on the ToxCast website
(http://epa.gov/ncct/toxcast/data.html, December 2013 release).
The in vitro HTS bioactivity data were not corrected using a cyto-
toxicity ﬁlter and reﬂect the publicly-available data from ToxCast™
Phase II at the time the database was accessed.
In enterocytes, in liver, and in other tissues in vivomany chemi-
cals with demonstrated estrogenic activity in vitro are inactivated
by conjugation to the glucuronide or sulfate (Strassburg et al.,
2002; Guillemette et al., 2004). Hence, the steady state concentra-
tions in plasma used to determine the EAR will be the bioactive
aglycone rather than the total that includes conjugated forms.
When using in vitro data as the source of activity concentrations,
the exposure estimate must be represented as either steady state
plasma concentrations derived from blood or urinary concentra-
tions, or from oral equivalent doses (see SF-1 in Supplemental
Information for a schematic diagram of the three dosimetric
levels—oral equivalents or external dose, steady state plasma con-
centrations, and urinary excretion values). Because the major por-
tion of GEN, as well as that of many other estrogenic chemicals,
exists in plasma as an inactive conjugate, it is necessary to express
both the exposure and activity levels as steady state plasma levels
of the active moiety. This approach also requires that urinary
excretion values of the chemical of interest be expressed as steady
state plasma levels of the bioactive aglycone.
For estimating activity values from in vivo animal data, Becker
et al. (2014) used a BMD value from the uterotrophic assay to
obtain the corresponding biomonitoring equivalent (BE) value;
thus, they expressed an external dose as a urinary concentration.
This enabled comparison of the human exposure values (mg/L in
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urine corresponding to the uterotrophic BMD. For estimating activ-
ity values, Wetmore et al. (2012) used an equation that included
plasma protein binding as well as renal and metabolic clearance
to predict a steady state blood concentration and a unitary dose
rate of 1 mg/kg/d; then, the ratio between the AC50 value from a
ToxCast™ assay and the predicted steady state concentration at
the unit dose provided the oral equivalent dose representing the
AC50 value from the assay. Since the Wetmore et al. (2012) report
did not include an oral equivalent dose calculation for GEN, the
EAR values for GEN are based on comparison of steady state plasma
levels. The EAR values for other chemicals will be based on com-
parison of oral-equivalent doses. Eqs. (1)–(3) below provide the
details of the calculations.
EAR ðunitlessÞ ¼ Exposure ðoral equiv:dose in mg=kg=dÞ
Activity ðAC50 oral equiv:dose in mg=kg=dÞ
ð1Þ
EARGEN ðunitlessÞ ¼GEN Exposure ðsteady state blood conc:in lMÞGEN Activity ðAC50 in lMÞ
ð2Þ
REEAQChem: ¼
EARChem:
EARGEN
ð3Þ
For GEN, steady state blood concentrations of the active uncon-
jugated compound were developed from measurements reported
in the literature (Arai et al., 2000; Busby et al., 2002; Cimino
et al., 1999; Grace et al., 2003, 2004; Liu et al., 2013; Richelle
et al., 2002; Setchell et al., 2003, 2011; Shelnutt et al., 2000,
2002; Shimazu et al., 2011; Takashima et al., 2004; Teeguarden
et al., 2011; Völkel et al., 2002; Yuan et al., 2012; Zhang et al.,
2003). To obtain the EAR value for GEN, the estimated steady state
plasma concentration GEN in human serum (see below) was divid-
ed by the AC50 value from each of the assays considered.
3. Derivation of steady state concentrations of GEN in human
serum
Because the major portion of GEN, as well as that of many other
putative estrogenic chemicals, exists in plasma as inactive conju-
gates, expressing both the exposure and activity levels as steady
state plasma levels of the active moiety is desirable. However, this
approach requires that urinary excretion values of the chemical ofFig. 1. Box plots of the distributions of free GEN in plasma from measurements of free G
values for free GEN range from 0.001 lM to about 0.02 lM, whereas those estimated frinterest also be expressed as steady state plasma levels. This par-
ticular IVIVE calculation proved challenging for bisphenol-A
(BPA) because urinary values grossly overestimate the unconjugat-
ed active moiety, and this may also be the case for other chemicals
as well (Teeguarden and Hanson-Drury, 2013; Teeguarden et al.,
2005, 2011, 2013).
Phase II glucuronidation and sulfation metabolically inactivate
GEN. Unfortunately, most analyses for GEN use a pre-treatment
of b-glucuronidase/sulfatase H-2 and report only total aglycone
concentrations following such enzymatic digestion (Zhang et al.,
2003). Early methods of analysis of both the aglycone and conju-
gates involved splitting the sample and using enzymes on one split
and not the other (Cimino et al., 1999; Shelnutt et al., 2000, 2002).
More recent studies employ LC/MS with 13C labeling, or HPLC-
diode array detection to perform simultaneous analysis of the agly-
cone and metabolites (Hosoda et al., 2011; Setchell et al., 2011).
These studies provide percentage values for the aglycone. The
results and calculation methods are shown in Supplementary
Information Table 1. From these three studies, a rounded value of
0.3% represents the aglycone in plasma.
Four studies provided measurements of the fraction of total
GEN in plasma existing as the aglycone (Busby et al., 2002;
Metzner et al., 2009; Setchell et al., 2011; Yuan et al., 2012). These
studies measured both the aglycone and the conjugate. Eight stud-
ies provided data for total GEN in plasma (Arai et al., 2000; Grace
et al., 2004; Heald et al., 2006; Iwasaki et al., 2008; Ritchie et al.,
2004; Setchell et al., 2003; Shimazu et al., 2011; Takashima et al.,
2004). The free GEN was estimated by multiplying the total GEN
value by 0.3%. Calculation methods and values are shown in
Supplementary Information.
The distributions of free GEN in plasma from measurements of
free GEN (left) and total GEN (right) are depicted in Fig. 1. The
median values for measurements of free GEN range from 0.001
to about 0.02 lM, whereas those estimated from total GEN mea-
surements range from 0.00001 to 0.001 lM. As noted, a value for
the unconjugated fraction of 0.003 was estimated from two more
recent papers (Hosoda et al., 2011; Setchell et al., 2011). An earlier
paper measured both free GEN before enzymatic digestion, and
sulfate and glucuronide conjugates following digestion, and
observed a value of 12.5% (Shelnutt et al., 2002).
There are three possible explanations for this approximately 30-
fold difference resulting in free GEN values greater than total GEN
values. First, in the four studies that measured free GEN, some
ex vivo hydrolysis of conjugates may have occurred. Second,
Hosoda et al. (2011) and Setchell et al. (2011) failed to measureEN (left) and total GEN (right). Plots are presented on the same scale. The median
om total GEN measurements range from 1E05 to 0.001 lM.
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from enzymes occurring in plasma. Third, Shelnutt et al. (2002)
may have overestimated the amount of free GEN because of con-
tamination of samples or glassware with sulfatase/glucuronidase
reagent.
If one assumes the measurement of Shelnutt et al. (2002) is cor-
rect and would use 12% as a measure of free GEN from total GEN,
then the two sets of measurements become more consistent. Here,
a value of 0.005 lM will be used as the steady state plasma con-
centration representing GEN exposure. It is representative of the
central value of the free GEN measurements and of the upper
end of the total GEN measurements.4. Deriving and interpreting EAR and REEAQ values from
ToxCastTM and Tox21 assay results
To calculate a REEAQ value as in Becker et al. (2014), two EAR
values are required: one for the chemical of interest and the other
for the reference chemical, in this case, GEN. For each of these EAR
values, estimates of exposure and activity are needed. All four of
the values required (two for each EAR) should be expressed in
the same units and represent a comparable biological quantity,
e.g., dose or tissue concentration.
For the set of substances evaluated, results from one of the
ToxCast™ assays (Attagene: human ERa reporter gene construct)
are depicted in Fig. 2. The AC50 results are presented in (a), the
EARs based on human exposures in (b), and the REEAQs (normal-
ized to the EARGEN) in (c). The assay ATG_ERa_TRANS had the most
positive chemical responses for which exposure information also
existed. Assay negatives resulted in a default EAR value of zero.
The chemicals were ordered by increasing EAR from left to right.
This order was maintained in all the other plots in Figs. 3 and 4.
Numerical values for EARs and REEAQs are provided in Supplemen-
tary Tables 3 and 4. In addition, exposure information was not
available in Wetmore et al. (2012) for all chemicals tested; chemi-
cals without exposure data were not included in the analysis.
Among the chemicals included in the analysis BPA, boscalid, cypro-
dinil, ethalﬂuralin and fenhexamid each exhibited an REEAQ
greater than 1 in one of the seven assays; 2-phenylphenol had
REEAQ values greater than 1 in three of the seven assays.5. Uncertainty in exposures estimates and in vitro-to-in vivo
extrapolation (IVIVE)
For exposure, estimation of oral-equivalent doses relied on the
methods used by Wetmore et al. (2012). For chemicals other than
GEN, IVIVE was required because the estrogen receptor-related
bioactivity of interest were expressed as in vitro concentrations;
Supplementary Information SF-1 shows a schematic for compar-
ison of the methodology in Becker et al. (2014), Wetmore et al.
(2012), and also that used here.
Hence, EAR values for GEN were derived directly from an esti-
mate of exposure measured as an in vivo blood concentration
and the AC50 with both values in units of concentration. However,
the EAR values for chemicals were derived using a generic IVIVE
dosimetry model for activity and existing chemical-speciﬁc dosi-
metric models of varying sophistication and accuracy (LaKind
et al., 2008). Hays et al. (2008) discuss some of the issues of esti-
mating oral-equivalent doses from measurements of chemicals or
their metabolites in urine, including length of half-life, identiﬁca-
tion and quantiﬁcation of all metabolites and hydration status.
Although the calculation of the two EAR values used to calculate
a REEAQ value have different starting points, the utility of REEAQ
values for priority screening and contextualizing results of HTS
assays remains clear.In applying the EAR and REEAQ methodologies beyond the
proof of concept stage, additional consideration may be warranted
for application of a statistical methodology to estimate the uncer-
tainty in the EAR and REEAQ values. Wetmore et al. (2012) present-
ed the range of exposure estimates obtained for various age- and
gender-based subpopulations and compared these to the distribu-
tion of the oral equivalent dose ranges required to achieve the
upper 95th percentile steady-state blood concentration across
the suite of in vitro assays. More recently, EPA illustrated uncer-
tainty by presenting the range of human exposure predictions
(from the median to upper 95-percentile values) compared to the
range from the median and minimum in vitro oral equivalent activ-
ity doses. Such visualizations can help to identify those EARs that
have the greatest degree of uncertainty or variability. One should
also keep in mind that the level of effort devoted towards charac-
terizing uncertainty should be commensurate with the impact and
importance of the decision, and in employing the EAR and REAAQ
methods for priority setting for endocrine screening, use of median
values may provide sufﬁcient precision to support prioritization
decisions.6. Discussion
The concept of relative potency has previously informed
prioritization processes for risk assessment. Toxicity equivalent
factors (TEFs) for human health risk assessment of 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD) and dioxin-like compounds are
derived from a consensus relative potency value, using TCDD as
the index chemical (Van den Berg et al., 1998, 2006) to standardize
the interpretation of AhR ligand responses by single chemicals or
aggregated mixtures. Indeed, one of the noted limitations of this
approach is that there are endogenous AhR ligands in healthy
human diets, and the TEF approach does not establish a safe
threshold based on dietary exposure (Safe, 1998; Van den Berg
et al., 2006). Environmental estrogen equivalents (EEQs) have
largely been used to evaluate the potential estrogenicity of envi-
ronmental matrices via standardization to 17b-estradiol potency,
i.e., assuming the same slope of the dose–response curve, in in vitro
bioassays (Avbersek et al., 2011; Bermudez et al., 2010, 2012).
Recently, a revision to the EEQ approach to derive assay-speciﬁc
thresholds of safety was proposed by deﬁning the amount of
17b-estradiol needed to obtain an effect in each assay (Jarosova
et al., 2014). The REEAQ approach advances this precedent by stan-
dardizing estrogenic activity to a well-understood dietary isoﬂa-
vone, and also incorporating potential human exposure, such that
both exposure and activity potential are used to rank chemicals
relative to genistein. This REEAQ approach thus provides a means
for establishing a threshold for chemicals that warrant further
investigation based on consideration of putative mode of action,
potency, and exposure. A chemical with high estrogenic potency
predicted from in vitro results, but with limited potential exposure,
would thereby be deprioritized in this comparison. This REEAQ
approach fulﬁlls a need for high-throughput prioritization of
potentially estrogenic chemicals for further testing in models of
greater biological complexity and reliability. Using a read-across
approach, the consensus REEAQ values could be used to prioritize
chemicals for further conﬁrmatory testing.6.1. The value of the REEAQ in priority decisions
Calculation of EAR and REEAQ values is relatively straightfor-
ward, assuming the activity and exposure values are available
and can be expressed in the same units. The utility of exposure:ac-
tivity proﬁling is readily seen in Fig. 2; striking differences are
apparent between evaluating activity only (Fig. 2(a)) versus
Fig. 2. Plots of (A) activity (AC50), (B) EAR and (C) REEAQ for ATG_ER_TRANS ToxCast™ assay. GEN is shown in red.
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ing just the ATG_ERa_TRANS ToxCast™ assay for priority setting
purposes, reliance on activity proﬁling would identify 20 of the
26 substances as having AC50 values in excess of genistein. But,
when EARs are used, only 1 of the 26 substances has an EAR valueexceeding EARGEN. And more than 50% have EAR values 100 times
lower than the EARGEN. There is variation in AC50 values across
ToxCast™ and Tox21 assays (Figs. 3 and 4), the same rank order
of potencies was not observed as in the EAR values. However, irre-
spective of the particular assays, the EAR and REEAQ methods can
Fig. 3. Ordered vertical bar plots for EAR (left column) and REEAQ values for the assays OT_ER_ERaERb_48, ATG_ERE_CIS, and OT_ERbERb_48. In all plots, GEN is shown in red.
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results.
Since GEN is a component of a healthy diet, and we have used
an estimate of the average GEN serum level in US population as
the exposure value for determining EAR and REEAQ values, those
substances with values substantially below the EARGEN would
seem to be candidates for deprioritization with respect to the EDSP
or similar endocrine screening/testing programs. Since risk is a
function of both exposure and hazard, EAR and REEAQ metrics pro-
vide a scientiﬁcally sound approach for placing HTS results into
context for use in setting priorities. It is important to note that,
because GEN is only very weak or lacks estrogenic effects at typical
exposures in humans (e.g., a high isoﬂavone diet induced only
slight effects and no clinically relevant effects on vaginal epitheli-
um or endometrium in postmenopausal women (Duncan et al.,
1999)) the REEAQ methodology reﬂects a high degree of conser-
vatism and is health protective for humans.
To capture uncertainty in the REEAQ approach that uses oral
exposure estimates derived from dosimetry models and activityestimates derived from IVIVE, an arbitrary, policy-based threshold
could be applied; for example, chemicals demonstrating REEAQ
values greater than 0.1 could be prioritized for further testing. This
REEAQ value could be adjusted based on obtaining greater conﬁ-
dence in the dosimetry and IVIVE models, resources available for
continued toxicity testing, or other factors and could contribute
to a value-of-information approach as part of EDSP21 prioritization
(NRC, 2007, 2009).
The challenges associated with IVIVE and dosimetry notwith-
standing, the use of the REEAQ value provides a straightforward
way to contextualize exposures to putative estrogenic substances.
Because the EAR and REEAQ metrics incorporate indications of
both potency and exposure, use of these metrics is preferred for
priority setting decisions rather than the use of activity values by
themselves (Morgan et al., 2013; Rotroff et al., 2014). This use of
exposure context is especially important when considering results
from sensitive in vitro HTS assays. The straightforward and scien-
tiﬁcally logical method of linking activity of a compound in a
HTS endocrine assay to the human exposure to that substance,
Fig. 4. Ordered vertical bar plots for EAR (left column) and REEAQ values for the assays ACEA_T47D_8hr_Negative, Tox21_ERA_LUC_BG1_Agonist, and Tox21_ERA_BLA_A-
gonist_ratio. In all plots, GEN is shown in red.
404 R.A. Becker et al. / Regulatory Toxicology and Pharmacology 71 (2015) 398–408and benchmarking this to the potency and exposure of a normal
dietary constituent, makes the REEAQ a useful communication tool
in discussions with a wide range of audiences about potential
concerns arising from detection of positive responses in HTS (or
similar in vitro or in vivo) endocrine screening assays.
6.2. The AC50 is the preferred measure of activity
Location and steepness are characteristics of every dose–
response curve (Slob and Setzer, 2014). Receptor-based responses,
such as those produced by endocrine-active substances, involve
many steps (Ong et al., 2010). A general assumption about the
dose–response curve for substances that act by receptor binding
is that a ﬁrst-order Hill function is generally able to provide a
mathematical description of the dose–response (Chow et al.,
2011). However, the assays considered here and other estrogen-related ToxCast™ and Tox21 assays measure events at different
points downstream of receptor binding. For example, ATG_ERa_-
TRANS, ATG_ERE_CIS, and Tox21_Era_LUC_BG1_Agonist measure
changes in transcriptional activity subsequent to ER activation,
though by orthogonal technologies, whereas the
ACEA_T47D_80hr_Positive and ACEA_T47D_80hr_Negative assays
measure estrogen-dependent cellular growth kinetics Rotroff
et al. (2013b). These latter two assays measure cellular events
much further downstream than the assays of ER transcriptional
activity, and could be expected to have steeper dose–response
curves (Chow et al., 2011; Ong et al., 2010). In fact, both a
ﬁrst- and a second-order Hill function ﬁt the data for the
Tox21_ERa_LUC_BG1_Agonist for 17b-estradiol equally well
(Simon et al., 2014). Since a diverse set of assays based on
measurement of different events along the ER activity pathway
are available for determining potential estrogen receptor
R.A. Becker et al. / Regulatory Toxicology and Pharmacology 71 (2015) 398–408 405interaction with xenobiotics, the most reliable measure of potency
is the AC50.
The importance of co-regulatory proteins in modulating estro-
gen-related gene expression is being recognized (Aarts et al.,
2013; Houtman et al., 2012; Wang et al., 2013). Competition for
coregulatory proteins may reduce the efﬁcacy of gene expression
responses at high ligand concentrations, a phenomenon known
as squelching (Kraus et al., 1995; Zhang and Teng, 2001). In fact,
squelching is apparent in the responses to GEN in measurements
of cellular growth kinetics and responses at high doses had to be
removed from the dose–response ﬁt (Rotroff et al., 2013b). Co-
regulatory proteins can modulate both potency and efﬁcacy in
estrogen-induced gene expression (Jeyakumar et al., 2008, 2011;
Simons, 2008; Simons and Kumar, 2013).
Some have discussed using LEC, or lowest effective concentra-
tion, of a chemical as the measure of comparative activity for endo-
crine related endpoints assays (Rotroff et al., 2010, 2014), Because
of the considerations of potency, efﬁcacy and slope discussed
above, an AC50 is the least variable dose–response metric, and thus
affords greater certainty than other metrics along the dose–re-
sponse curve. For all these reasons, the AC50 is the most appropri-
ate metric to use as the activity component for EAR calculations.
6.3. Potential future uses of the REEAQ methodology for androgen,
thyroid and steroidogenesis pathways
For endocrine priority setting, the ToxCast™ and Tox21 assays
have focused on evaluating estrogen, androgen, thyroid, and
steroidogenesis pathways. The selection of substances for contex-
tualizing androgen, thyroid and steroidogenesis assay results in a
manner similar to GEN for estrogen assays results will require
some additional investigation.
Much continuing effort surrounds the integration of multiple
assays of estrogenic activity into a single interpretation of the
potential to drive estrogen receptor (ER) activity. The new
approach of Rotroff et al. (2014) in which a composite ER Interac-
tion Score is derived by integrating responses across ToxCast™
assays for estrogen receptor activity does just this. Though this
model provides a ranked estrogen score using binding, agonist,
antagonist, and ER-related growth signals, this score is unitless,
and is not immediately available for utilization in exposure:ac-
tivity proﬁling. Moreover, this method appears to compress mea-
sures of potency that differ by 1000–10,000-fold to a scale where
scores differ only by a factor of 2–3-fold. Thus, a direct expo-
sure:activity proﬁling approach would require incorporation of
potencies and conversion of the ER interaction scores into concen-
trations that could be converted to oral equivalent doses using
dosimetric approaches. While the ER Interaction Score solves the
problem of using single assays with different strengths and vul-
nerabilities for false positives and negatives, it does not directly
address the need to incorporate exposure information context for
prioritization of further testing. A simpler, more straightforward
approach would be to derive an EAR value from results of each
assay and then calculate a mean EAR value for each substance
across all the assays. Comparison could then be made amongst
the mean EARs and the mean EARGEN. In this manner, strengths
and limitations of the assays are normalized and exposure:activity
proﬁling can be accomplished.
While this proof of concept has shown the utility of the EAR and
REEAQ approach for priority setting for estrogen activity, wider
application poses a number of challenges. First and foremost, as
discussed by Borgert et al. (2013), thresholds govern endocrine
activity, and even though activities may be observed from in vitro
estrogen assays, and EARs could theoretically be calculated, sub-
stances with low potencies are likely not to be biologically active
in vivo. Thus, in addition to developing an REEAQ cutoff value fordeprioritization, consideration should also be given to developing
activity cut off values for each hormonal system. Substances with
activity values lower than these cutoff values could be depri-
oritized based on activity alone, and not require calculation of
EAR values.
To utilize the EAR and REEAQ approach for androgen and thy-
roid pathways, suitable reference agents must be identiﬁed. Previ-
ously, as an androgen reference material, we suggested
investigating the possibility of using 3,3-diindolylmethane (formed
during digestion of cruciferous vegetables), it is commercially
available (e.g., SigmaAldrich) and has been described as a ‘‘natural-
ly occurring pure androgen antagonist’’ (Le et al., 2003). To date,
there are not enough HTS assay data to adequately classify putative
thyrotoxicants, largely because not all modes of action for thyroid
disruption are evaluated by current ToxCast™ or Tox21 assay tools
(Rotroff et al., 2013a; Paul et al., 2014). For thyroid applications, a
family of active compounds would likely be needed to address dif-
ferent molecular initiating events that result in thyroid perturba-
tion, including thyroperoxidase inhibition, sodium-symporter
inhibition, deiodinase inhibition, upregulation of hepatic catabo-
lism, interference with serum binding proteins, and interactions
with thyroid hormone receptors (Murk et al., 2013; Crofton,
2008). Glucosinolate metabolites, such as 5-vinyloxazolidine-2-
thione or various isothiocyanates/thiocyanates derived from
numerous vegetables (e.g., broccoli, cabbage, cauliﬂower, radish,
turnip) may be candidates for a thyroid iodine uptake inhibitor ref-
erence compound (Crozier et al., 2006). Soy isoﬂavones including
genistein are known to inhibit thyroperoxidase in vivo and
ex vivo, but only result in systemic thyroid disruption with coinci-
dence of iodine deﬁciency (Doerge and Chang, 2002). It may be
necessary to identify several reference chemicals in this manner
in order to evaluate REEAQs for in vitro thyroid activity. Additional
efforts to improve the available HTS assays for thyroid and
steroidogenesis disruption, and to identify and evaluate potential
reference substances for these pathways, should be a priority for
EDSP21.
Key to implementing exposure:activity proﬁling for priority set-
ting and screening is overcoming the challenge of obtaining suit-
able exposure estimates. To address such challenges,
considerable efforts have been devoted over the last few years in
exploring high throughput exposure modeling approaches, includ-
ing the ExpoCast (Wambaugh et al., 2013) and ExpoDat (Armitage
et al., 2014) research programs. Integral to these approaches is
research that translates bioactivity concentrations in HTS in vitro
assays to concentrations of the chemical in the target tissue or
blood in vivo (Yoon et al., 2014). Since development of exposure
estimates is the rate-limiting step for expanding HTS exposure:ac-
tivity proﬁling, research to develop and establish scientiﬁc conﬁ-
dence in rapid high throughput predictions of internal
concentrations needs to be a priority. EPA is modifying the
Stochastic Human Exposure and Dose Simulation model to enable
coupling of high throughput modeling with toxicokinetic modeling
to be used in a forward dosimetry process (USEPA, 2014a). This
approach appears to have considerable promise. The approach
could provide a useful basis for generating conservative, screening
level, predictions of internal concentrations that can then be
matched to HTS results from ToxCast™ and Tox21 assays for pri-
ority setting. While such screening level estimates of exposure
may be suitable for many chemicals, particularly where exposure
data is lacking, a more reﬁned approach may be appropriate for
other chemicals. Thus, even at the level of priority setting, consid-
eration should be given to implementing a tiered exposure assess-
ment framework, which encourages generation and use of reﬁned
exposure estimates/data as a substitute for modeled estimates,
when such reﬁned estimates/data can be shown to be relevant
and reliable.
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